Navigation Links
JNCI news brief: Antibody linked to chemotherapy drug inhibits ovarian cancer in lab
Date:7/29/2009

A novel anticancer agent, consisting of a monoclonal antibody linked to a chemotherapy drug, showed substantial antitumor activity in ovarian cancer cell lines and in mice, according to a study published online July 29 in the Journal of the National Cancer Institute.

The agent, known as an immunoconjugate, targets a protein, EphA2, which is overexpressed in many human cancers but is absent or expressed at low levels in normal tissues.

Anil K. Sood, M.D., of The University of Texas M.D. Anderson Cancer Center in Houston, and colleagues tested the immunoconjugate in ovarian cancer cell lines, where it bound to cells with high levels of EphA2 but not to those without the protein. In mice, the EphA2 immunoconjugate inhibited tumor growth by 85%󈟎% compared with that in mice treated with a control immunoconjugate, a highly statistically significant difference. In cell lines, its antitumor effects were also statistically significantly related to decreased proliferation and increased apoptosis of tumor cells.

Chemotherapy drugs typically affect both tumor and normal tissues, which can result in side effects. The immunoconjugate tested by the in this study allows for highly selective delivery of chemotherapy. "In summary," the authors write, "the findings herein provide a novel EphA2-targeted immunoconjugate with potent antitumor activity in ovarian carcinoma. Further preclinical and clinical developmentappears to be warranted."


'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Page: 1

Related medicine news :

1. In brief: New prognostic indicator for patients with IPF
2. JNCI news brief: Improving the biomarker pipeline for early cancer detection
3. JNCI news brief: Hepatitis B virus mutations may predict risk of liver cancer
4. JNCI news brief: Breast cancer hormone receptor status and risk of a second primary tumor
5. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
6. Antibody leads to repair of myelin sheath in lab study of multiple sclerosis and related disorders
7. Antibody Helps Repair MS Nerve Damage
8. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
9. ThromboGenics Begins Preclinical Development of Anti-VPAC Antibody for Thrombocytopenia
10. Antibody responses in patients with Lyme arthritis
11. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... ... April 30, 2016 , ... Orlando-based Maximized Living has selected Dr. ... gold in Rio. Under the care of Maximized Living doctors at the London ... unprecedented showing, Maximized Living is sending the largest contingent of elite chiropractors to Rio ...
(Date:4/29/2016)... ... April 29, 2016 , ... Memorial Healthcare System Graduate ... Education (ACGME) that it has received accreditation for its residency program on Physical ... programs that Memorial is currently pursuing, including Pediatrics and Internal Medicine. This accreditation ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related ... 2016 and podcasted thereafter . Dr. Bernie Siegel, author of a plethora ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a comprehensive spine physician ... one of their physicians has been invited to be a featured speaker at the ... Review conference on April 30, 2016. , Dr. R. Scott McPherson, a physical ...
(Date:4/29/2016)... ... 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about 1 ... skin cancer deaths. More than 10,000 people are expected to die of melanoma this year. ... is the one of the most commonly diagnosed cancers in young women. A recent breakthrough ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 2016 Tie-up with Government hospitals ... to save newborns   Fortis La Femme, ... in collaboration with Breast Milk Foundation (BMF), a non-profit organization ... Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit centre recognizes ... infants and should be available to babies deprived of mother,s ...
(Date:4/27/2016)... 2016 Oasmia Pharmaceutical AB ... a new generation of drugs within human and ... for Paclical/Apealea in the Phase III study that ... ovarian cancer. These preliminary results showed non-inferiority between ... carboplatin versus Taxol in combination with carboplatin. In ...
(Date:4/26/2016)... FLINT, Mich. , April 26, 2016 ... the promotion of Jennifer Hagerman , Pharm D., ... In her growing role at Diplomat, Hagerman will continue ... of the company that delivers custom education and training ... to the specialty pharmacy industry. Diplomat University also houses ...
Breaking Medicine Technology: